The DOI matches its Crossref record; 302 of the 302 references it cites were found in a registry or an index.
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Open accessAbstract
Tumor growth and metastasis rely on tumor vascular network for the adequate supply of oxygen and nutrients. Tumor angiogenesis relies on a highly complex program of growth factor signaling, endothelial cell (EC) proliferation, extracellular matrix (ECM) remodeling, and stromal cell interactions. Numerous pro-angiogenic drivers have been identified, the most important of which is the vascular endothelial growth factor (VEGF). The importance of pro-angiogenic inducers in tumor growth, invasion and extravasation make them an excellent therapeutic target in several types of cancers. Hence, the number of anti-angiogenic agents developed for cancer treatment has risen over the past decade, with at least eighty drugs being investigated in preclinical studies and phase I-III clinical trials. To date, the most common approaches to the inhibition of the VEGF axis include the blockade of VEGF receptors (VEGFRs) or ligands by neutralizing antibodies, as well as the inhibition of receptor tyrosine kinase (RTK) enzymes. Despite promising preclinical results, anti-angiogenic monotherapies led only to mild clinical benefits. The minimal benefits could be secondary to primary or acquired resistance, through the activation of alternative mechanisms that sustain tumor vascularization and growth. Mechanisms of resistance are categorized into VEGF-dependent alterations, non-VEGF pathways and stromal cell interactions. Thus, complementary approaches such as the combination of these inhibitors with agents targeting alternative mechanisms of blood vessel formation are urgently needed. This review provides an updated overview on the pathophysiology of angiogenesis during tumor growth. It also sheds light on the different pro-angiogenic and anti-angiogenic agents that have been developed to date. Finally, it highlights the preclinical evidence for mechanisms of angiogenic resistance and suggests novel therapeutic approaches that might be exploited with the ultimate aim of overcoming resistance and improving clinical outcomes for patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Isolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,855
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559 · cited 1×
“This process, referred to as the angiogenic switch, from an avascular state to an angiogenic phase, is crucial for tumors to grow and continue unrestricted proliferation (7).”
BackgroundVEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 2×
“As a result of protecting ECs from anti-angiogenic agents, pericytes were implicated in clinical resistance to VEGFR inhibitors (249).”
BackgroundRoberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V, & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,866
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 3×
“They also secrete MMPs, promotingangiogenesis (198, 226, 229, 230).”
BackgroundFibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
Massagué, J., Blain, S. W., & Lo, R. S. (2000) · Cell · doi:10.1016/s0092-8674(00)00121-5 · Cited by 2,385
Macrophage plasticity and polarization in tissue repair and remodelling
Mantovani, A., Biswas, S. K., Galdiero, M. R., Sica, A., & Locati, M. (2013) · The Journal of Pathology · doi:10.1002/path.4133 · Cited by 2,384 · cited 1×
“They also secrete MMPs, promotingangiogenesis (198, 226, 229, 230).”
BackgroundPàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry
Maniotis, A. J., Folberg, R., Hess, A., Seftor, E. A., Gardner, L. M. G., Pe'er, J., Trent, J. M., Meltzer, P. S., & Hendrix, M. J. C. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65173-5 · Cited by 2,043
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Friends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1477 · Cited by 1,765
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001) · Nature Medicine · doi:10.1038/87904 · Cited by 1,672
Isolation of a tumor factor responsible for angiogenesis
Folkman, J., Merler, E., Abernathy, C., & Williams, G. (1971) · The Journal of Experimental Medicine · doi:10.1084/jem.133.2.275 · Cited by 1,663
The role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Changing views of the role of matrix metalloproteinases in metastasis
Chambers, A. F., & Matrisian, L. M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.17.1260 · Cited by 1,588
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,573
Tumor Cell Interactions with the Extracellular Matrix During Invasion and Metastasis
Stetler-Stevenson, W. G., Aznavoorian, S., & Liotta, L. A. (1993) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.09.110193.002545 · Cited by 1,526
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
Solinas, G., Germano, G., Mantovani, A., & Allavena, P. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0609385 · Cited by 1,425
Karkkainen, M. J., Haiko, P., Sainio, K., Partanen, J., Taipale, J., Petrova, T. V., Jeltsch, M., Jackson, D. G., Talikka, M., Rauvala, H., et al. (2004) · Nature Immunology · doi:10.1038/ni1013 · Cited by 1,421
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
De Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311
Adamis, A. P., Miller, J. W., Bernal, M.-T., D'Amico, D. J., Folkman, J., Yeo, T.-K., & Yeo, K.-T. (1994) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)75794-0 · Cited by 1,296
Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice
Jeltsch, M., Kaipainen, A., Joukov, V., Meng, X., Lakso, M., Rauvala, H., Swartz, M., Fukumura, D., Jain, R. K., & Alitalo, K. (1997) · Science · doi:10.1126/science.276.5317.1423 · Cited by 1,283
VEGF-D promotes the metastatic spread of tumor cells via the lymphatics
Stacker, S. A., Caesar, C., Baldwin, M. E., Thornton, G. E., Williams, R. A., Prevo, R., Jackson, D. G., Nishikawa, S.-I., Kubo, H., & Achen, M. G. (2001) · Nature Medicine · doi:10.1038/84635 · Cited by 1,246
MET signalling: principles and functions in development, organ regeneration and cancer
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3012 · Cited by 1,240
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Achen, M. G., Jeltsch, M., Kukk, E., Mäkinen, T., Vitali, A., Wilks, A. F., Alitalo, K., & Stacker, S. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.548 · Cited by 1,205
Signaling Vascular Morphogenesis and Maintenance
Hanahan, D. (1997) · Science · doi:10.1126/science.277.5322.48 · Cited by 1,190
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Fantin, A., Vieira, J. M., Gestri, G., Denti, L., Schwarz, Q., Prykhozhij, S., Peri, F., Wilson, S. W., & Ruhrberg, C. (2010) · Blood · doi:10.1182/blood-2009-12-257832 · Cited by 1,153
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140
Du, R., Lu, K. V., Petritsch, C., Liu, P., Ganss, R., Passegué, E., Song, H., VandenBerg, S., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,130
VEGF-Induced Adult Neovascularization: Recruitment, Retention, and Role of Accessory Cells
Grunewald, M., Avraham, I., Dor, Y., Bachar-Lustig, E., Itin, A., Yung, S., Chimenti, S., Landsman, L., Abramovitch, R., & Keshet, E. (2006) · Cell · doi:10.1016/j.cell.2005.10.036 · Cited by 1,126
Park, J. E., Chen, H. H., Winer, J., Houck, K. A., & Ferrara, N. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47298-5 · Cited by 1,112
Macrophages Regulate the Angiogenic Switch in a Mouse Model of Breast Cancer
Lin, E. Y., Li, J.-F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., Qian, H., Xue, X.-N., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1278 · Cited by 1,074
Jabłońska-Trypuć, A., Matejczyk, M., & Rosochacki, S. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2016.1161620 · Cited by 1,042
Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.
Maglione, D., Guerriero, V, Viglietto, G., Delli-Bovi, P., & Persico, M. G. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.9267 · Cited by 999
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 990
The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis
Sternlicht, M. D., Lochter, A., Sympson, C. J., Huey, B., Rougier, J.-P., Gray, J. W., Pinkel, D., Bissell, M. J., & Werb, Z. (1999) · Cell · doi:10.1016/s0092-8674(00)81009-0 · Cited by 924
Derynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., & Berger, W. H. (1987) · PubMed · Cited by 898
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892
Brown, L. F., Yeo, K. T., Berse, B., Yeo, T. K., Senger, D. R., Dvorak, H. F., & van de Water, L. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.5.1375 · Cited by 878
VEGF-receptor signal transduction
Cross, M. J., Dixelius, J., Matsumoto, T., & Claesson-Welsh, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00193-2 · Cited by 864
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S., & Kuliopulos, A. (2005) · Cell · doi:10.1016/j.cell.2004.12.018 · Cited by 838
Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma
Hendrix, M. J. C., Seftor, E. A., Hess, A. R., & Seftor, R. E. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1092 · Cited by 824
Escudier, B., Bellmunt, J., Négrier, S., Bajetta, E., Melichar, B., Bracarda, S., Ravaud, A., Golding, S., Jethwa, S., & Sneller, V. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7849 · Cited by 800
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O'Brien, S. M., Davis, R. B., Gowen, L. C., et al. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 775
SERAFINI, P., BORRELLO, I., & BRONTE, V (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 762
Sethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C., Salter, D., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Strieter, R., et al. (1999) · Nature Medicine · doi:10.1038/9511 · Cited by 739
Matrix Metalloproteinases Regulate Neovascularization by Acting as Pericellular Fibrinolysins
Hiraoka, N., Allen, E., Apel, I. J., Gyetko, M. R., & Weiss, S. J. (1998) · Cell · doi:10.1016/s0092-8674(00)81768-7 · Cited by 712
Kukk, E., Lymboussaki, A., Taira, S., Kaipainen, A., Jeltsch, M., Joukov, V., & Alitalo, K. (1996) · Development · doi:10.1242/dev.122.12.3829 · Cited by 690
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
Kowanetz, M., Wu, X., Lee, J., Tan, M., Hagenbeek, T., Qu, X., Yu, L., Ross, J., Korsisaari, N., Cao, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015855107 · Cited by 663
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 657
Bv8 regulates myeloid-cell-dependent tumour angiogenesis
Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X.-H., Yao, J., Blanchard, D., Bais, C., Peale, F. V., van Bruggen, N., et al. (2007) · Nature · doi:10.1038/nature06348 · Cited by 644
Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639
Shepro, D., & Morel, N. M. L. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.11.8370472 · Cited by 635
FERRARA, N. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70064-x · Cited by 623
Targeting the TGFβ pathway for cancer therapy
Neuzillet, C., Tijeras-Raballand, A., Cohen, R., Cros, J., Faivre, S., Raymond, E., & de Gramont, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.001 · Cited by 611
Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells.
Orlidge, A., & D'Amore, P. A. (1987) · The Journal of cell biology · doi:10.1083/jcb.105.3.1455 · Cited by 611
Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells
Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., & Bronte, V. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00602.x · Cited by 608
The SDF-1–CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis
Petit, I., Jin, D., & Rafii, S. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.05.007 · Cited by 603
Cancer related inflammation: the macrophage connection
Sica, A., Allavena, P., & Mantovani, A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.028 · Cited by 601
Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Petrelli, N. J., Colangelo, L. H., Atkins, J. N., Seay, T. E., Fehrenbacher, L., Goldberg, R. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.0855 · Cited by 593
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
Poon, R. T.-P., Fan, S.-T., & Wong, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1207 · Cited by 587
Tumour vascularization: sprouting angiogenesis and beyond
Hillen, F., & Griffioen, A. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9094-7 · Cited by 583
Madri, J. A., Pratt, B. M., & Tucker, A. M. (1988) · The Journal of cell biology · doi:10.1083/jcb.106.4.1375 · Cited by 573
Abramsson, A., Lindblom, P., & Betsholtz, C. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18549 · Cited by 562
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.037 · Cited by 550
Ferrara, N. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37264 · Cited by 546
Bauvois, B. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.10.001 · Cited by 543
Targeting the PDGF signaling pathway in tumor treatment
Heldin, C.-H. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-97 · Cited by 540
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530
de Gramont, A., Van Cutsem, E., Schmoll, H.-J., Tabernero, J., Clarke, S., Moore, M. J., Cunningham, D., Cartwright, T. H., Hecht, J. R., Rivera, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70509-0 · Cited by 529
Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Rubenstein, J. L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D. F., & Shuman, M. A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900102 · Cited by 509
Willett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 508
Venneri, M. A., Palma, M. D., Ponzoni, M., Pucci, F., Scielzo, C., Zonari, E., Mazzieri, R., Doglioni, C., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2006-10-053504 · Cited by 505
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 485
Pietras, K., & Hanahan, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.093 · Cited by 479
Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902280106 · Cited by 471
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
Frentzas, S., Simoneau, E., Bridgeman, V. L., Vermeulen, P. B., Foo, S., Kostaras, E., Nathan, M. R., Wotherspoon, A., Gao, Z.-H., Shi, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4197 · Cited by 454
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445
Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness
Topczewska, J. M., Postovit, L.-M., Margaryan, N. V., Sam, A., Hess, A. R., Wheaton, W. W., Nickoloff, B. J., Topczewski, J., & Hendrix, M. J. C. (2006) · Nature Medicine · doi:10.1038/nm1448 · Cited by 438
Semaphorins and their Signaling Mechanisms
Alto, L. T., & Terman, J. R. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6448-2_1 · Cited by 429
Willett, C. G., Boucher, Y., Duda, D. G., di Tomaso, E., Munn, L. L., Tong, R. T., Kozin, S. V., Petit, L., Jain, R. K., Chung, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5635 · Cited by 420
Folkman, J. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00133-5 · Cited by 415
Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
Roskoski, R. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.156 · Cited by 412
Capece, D., Fischietti, M., Verzella, D., Gaggiano, A., Cicciarelli, G., Tessitore, A., Zazzeroni, F., & Alesse, E. (2013) · BioMed Research International · doi:10.1155/2013/187204 · Cited by 408
Sennino, B., Ishiguro-Oonuma, T., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V., Tabruyn, S. P., You, W.-K., Chapman, H. A., Christensen, J. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0240 · Cited by 408
Lee, J., Gray, A., Yuan, J., Luoh, S. M., Avraham, H., & Wood, W. I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.1988 · Cited by 401
Ristimäki, A., Narko, K., Enholm, B., Joukov, V., & Alitalo, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.14.8413 · Cited by 400
Rini, B. I., Michaelson, M. D., Rosenberg, J. E., Bukowski, R. M., Sosman, J. A., Stadler, W. M., Hutson, T. E., Margolin, K., Harmon, C. S., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5416 · Cited by 393
Understanding the biology of angiogenesis: Review of the most important molecular mechanisms
Otrock, Z. K., Mahfouz, R. A. R., Makarem, J. A., & Shamseddine, A. I. (2007) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2007.04.001 · Cited by 386
Self-citationVascular endothelial growth factor family of ligands and receptors: Review
Otrock, Z. K., Makarem, J. A., & Shamseddine, A. I. (2007) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2006.12.003 · Cited by 376
Self-citationAnti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
Sitohy, B., Nagy, J. A., & Dvorak, H. F. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3406 · Cited by 360
Holmgaard, R. B., Schaer, D. A., Li, Y., Castaneda, S. P., Murphy, M. Y., Xu, X., Inigo, I., Dobkin, J., Manro, J. R., Iversen, P. W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0356-4 · Cited by 356
Maglione, D. (1991) · Medical Entomology and Zoology · Cited by 352
Chun, T.-H., Sabeh, F., Ota, I., Murphy, H., McDonagh, K. T., Holmbeck, K., Birkedal-Hansen, H., Allen, E. D., & Weiss, S. J. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200405001 · Cited by 349
Coffelt, S. B., Tal, A. O., Scholz, A., De Palma, M., Patel, S., Urbich, C., Biswas, S. K., Murdoch, C., Plate, K. H., Reiss, Y., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0012 · Cited by 343
Ferrari, G., Cook, B. D., Terushkin, V., Pintucci, G., & Mignatti, P. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21706 · Cited by 340
Intussusceptive Angiogenesis: Its Role in Embryonic Vascular Network Formation
Djonov, V., Schmid, M., Tschanz, S. A., & Burri, P. H. (2000) · Circulation Research · doi:10.1161/01.res.86.3.286 · Cited by 339
Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
Shojaei, F., Singh, M., Thompson, J. D., & Ferrara, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712185105 · Cited by 334
Bellomo, D., Headrick, J. P., Silins, G. U., Paterson, C. A., Thomas, P. S., Gartside, M., Mould, A., Cahill, M. M., Tonks, I. D., Grimmond, S. M., et al. (2000) · Circulation Research · doi:10.1161/01.res.86.2.e29 · Cited by 333
Löhr, M. J., Schmidt, C., Ringel, J., Kluth, M., Müller, P., Nizze, H., & Jesnowski, R. (2001) · PubMed · Cited by 325
HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
Shojaei, F., Lee, J. H., Simmons, B. H., Wong, A., Esparza, C. O., Plumlee, P. A., Feng, J., Stewart, A. E., Hu-Lowe, D. D., & Christensen, J. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0489 · Cited by 319
Expression of Tie-2 by Human Monocytes and Their Responses to Angiopoietin-2
Murdoch, C., Tazzyman, S., Webster, S., & Lewis, C. E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.7405 · Cited by 318
Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
André, F., Bachelot, T., Campone, M., Dalenc, F., Perez-Garcia, J. M., Hurvitz, S. A., Turner, N., Rugo, H., Smith, J. W., Deudon, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0190 · Cited by 311
Jung, H.-Y., Fattet, L., & Yang, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3173 · Cited by 309
Gotzmann, J., Mikula, M., Eger, A., Schulte-Hermann, R., Foisner, R., Beug, H., & Mikulits, W. (2004) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(03)00033-4 · Cited by 305
Chae, Y. K., Ranganath, K., Hammerman, P. S., Vaklavas, C., Mohindra, N., Kalyan, A., Matsangou, M., Costa, R., Carneiro, B., Villaflor, V. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14109 · Cited by 298
VEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis
Dong, J., Grunstein, J., Tejada, M., Peale, F., Frantz, G., Liang, W., Bai, W., Yu, L., Kowalski, J., Liang, X., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600289 · Cited by 295
Neutrophils Promote the Malignant Glioma Phenotype through S100A4
Liang, J., Piao, Y., Holmes, L., Fuller, G. N., Henry, V., Tiao, N., & de Groot, J. F. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1279 · Cited by 280
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
Hart, K. C., Robertson, S. C., Kanemitsu, M. Y., Meyer, A. N., Tynan, J. A., & Donoghue, D. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203650 · Cited by 276
Donnem, T., Hu, J., Ferguson, M., Adighibe, O., Snell, C., Harris, A. L., Gatter, K. C., & Pezzella, F. (2013) · Cancer Medicine · doi:10.1002/cam4.105 · Cited by 275
Unraveling the Role of Angiogenesis in Cancer Ecosystems
Zuazo-Gaztelu, I., & Casanovas, O. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00248 · Cited by 275
Sandhu, S. K., Papadopoulos, K., Fong, P. C., Patnaik, A., Messiou, C., Olmos, D., Wang, G., Tromp, B. J., Puchalski, T. A., Balkwill, F., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2099-8 · Cited by 272
Matrix metalloproteinases: roles in cancer and metastasis
Fingleton, B. (2006) · Frontiers in Bioscience · doi:10.2741/1811 · Cited by 271
Molecular Determinants of Ovarian Cancer Plasticity
Sood, A. K., Seftor, E. A., Fletcher, M. S., Gardner, L. M. G., Heidger, P. M., Buller, R. E., Seftor, R. E. B., & Hendrix, M. J. C. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64079-5 · Cited by 268
El‐Kenawi, A. E., & El‐Remessy, A. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12344 · Cited by 253
Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C. C., & De Palma, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.059 · Cited by 247
Rock, E. P., Goodman, V., Jiang, J. X., Mahjoob, K., Verbois, S. L., Morse, D., Dagher, R., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-107 · Cited by 247
Neural guidance molecules regulate vascular remodeling and vessel navigation
Eichmann, A., Makinen, T., & Alitalo, K. (2005) · Genes & Development · doi:10.1101/gad.1305405 · Cited by 245
Antiangiogenic therapies for high-grade glioma
Norden, A. D., Drappatz, J., & Wen, P. Y. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.159 · Cited by 245
Angiopoietin signaling in the vasculature
Eklund, L., & Saharinen, P. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.03.011 · Cited by 242
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240
Deryugina, E. I., & Quigley, J. P. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.09.017 · Cited by 238
Hanrahan, V., Currie, M. J., Gunningham, S. P., Morrin, H. R., Scott, P. A., Robinson, B. A., & Fox, S. B. (2003) · The Journal of Pathology · doi:10.1002/path.1339 · Cited by 234
Larcher, F., Murillas, R., Bolontrade, M., Conti, C. J., & Jorcano, J. L. (1998) · Oncogene · doi:10.1038/sj.onc.1201928 · Cited by 231
Leenders, W. P. J., Küsters, B., Verrijp, K., Maass, C., Wesseling, P., Heerschap, A., Ruiter, D., Ryan, A., & de Waal, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0823 · Cited by 231
Piao, Y., Liang, J., Holmes, L., Zurita, A. J., Henry, V., Heymach, J. V., & de Groot, J. F. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos158 · Cited by 227
Angiogenesis: basic pathophysiology and implications for disease
Felmeden, D. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00635-8 · Cited by 220
van der Schaft, D. W. J., Seftor, R. E. B., Seftor, E. A., Hess, A. R., Gruman, L. M., Kirschmann, D. A., Yokoyama, Y., Griffioen, A. W., & Hendrix, M. J. C. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh267 · Cited by 219
Reinmuth, N., Liu, W., Jung, Y. D., Ahmad, S. A., Shaheen, R. M., Fan, F., Bucana, C. D., McMahon, G., Gallick, G. E., & Ellis, L. M. (2001) · The FASEB Journal · doi:10.1096/fj.00-0693fje · Cited by 214
The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy
van Beijnum, J. R., Nowak-Sliwinska, P., Huijbers, E. J. M., Thijssen, V. L., & Griffioen, A. W. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010215 · Cited by 211
Overexpression of VEGF and Angiopoietin 2: A Key to High Vascularity of Hepatocellular Carcinoma?
Moon, W. S., Rhyu, K. H., Kang, M. J., Lee, D. G., Yu, H. C., Yeum, J. H., Koh, G. Y., & Tarnawski, A. S. (2003) · Modern Pathology · doi:10.1097/01.mp.0000071841.17900.69 · Cited by 210
Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Petrelli, N. J., Lopa, S. H., & Wolmark, N. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4711 · Cited by 209
Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
Zhuang, G., Brantley-Sieders, D. M., Vaught, D., Yu, J., Xie, L., Wells, S., Jackson, D., Muraoka-Cook, R., Arteaga, C., & Chen, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1845 · Cited by 208
Angiopoietin‐2 expression in breast cancer correlates with lymph node invasion and short survival
Sfiligoi, C., de Luca, A., Cascone, I., Sorbello, V., Fuso, L., Ponzone, R., Biglia, N., Audero, E., Arisio, R., Bussolino, F., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10851 · Cited by 203
Dineen, S. P., Lynn, K. D., Holloway, S. E., Miller, A. F., Sullivan, J. P., Shames, D. S., Beck, A. W., Barnett, C. C., Fleming, J. B., & Brekken, R. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6705 · Cited by 203
Jahangiri, A., De Lay, M., Miller, L. M., Carbonell, W. S., Hu, Y.-L., Lu, K., Tom, M. W., Paquette, J., Tokuyasu, T. A., Tsao, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1281 · Cited by 202
Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
LeCouter, J., Lin, R., Tejada, M., Frantz, G., Peale, F., Hillan, K. J., & Ferrara, N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337667100 · Cited by 201
Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma
Helfrich, I., Edler, L., Sucker, A., Thomas, M., Christian, S., Schadendorf, D., & Augustin, H. G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1615 · Cited by 201
Couffinhal, T., Kearney, M., Witzenbichler, B., Chen, D., Murohara, T., Losordo, D. W., Symes, J. F., & Isner, J. M. (1997) · Europe PMC (PubMed Central) · Cited by 199
Tumor Cell Plasticity in Ewing Sarcoma, an Alternative Circulatory System Stimulated by Hypoxia
van der Schaft, D. W. J., Hillen, F., Pauwels, P., Kirschmann, D. A., Castermans, K., oude Egbrink, M. G. A., Tran, M. G. B., Sciot, R., Hauben, E., Hogendoorn, P. C. W., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2468 · Cited by 199
HIFs, angiogenesis, and cancer
Yang, Y., Sun, M., Wang, L., & Jiao, B. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24438 · Cited by 191
Stoeltzing, O., Ahmad, S. A., Liu, W., McCarty, M. F., Wey, J. S., Parikh, A. A., Fan, F., Reinmuth, N., Kawaguchi, M., Bucana, C. D., et al. (2003) · PubMed · Cited by 188
Signalling pathways in vasculogenic mimicry
Paulis, Y. W. J., Soetekouw, P. M. M. B., Verheul, H. M. W., Tjan-Heijnen, V. C. G., & Griffioen, A. W. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.01.001 · Cited by 188
Roland, C. L., Dineen, S. P., Lynn, K. D., Sullivan, L. A., Dellinger, M. T., Sadegh, L., Sullivan, J. P., Shames, D. S., & Brekken, R. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0280 · Cited by 188
Transforming growth factor-β in breast cancer: too much, too late
Barcellos-Hoff, M. H., & Akhurst, R. J. (2009) · Breast Cancer Research · doi:10.1186/bcr2224 · Cited by 187
Maione, F., Capano, S., Regano, D., Zentilin, L., Giacca, M., Casanovas, O., Bussolino, F., Serini, G., & Giraudo, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58976 · Cited by 187
Goede, V, Coutelle, O., Neuneier, J., Reinacher-Schick, A., Schnell, R., Koslowsky, T. C., Weihrauch, M. R., Cremer, B., Kashkar, H., Odenthal, M., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605925 · Cited by 186
Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer
Sakurai, A., Doci, C., & Gutkind, J. S. (2012) · Cell Research · doi:10.1038/cr.2011.198 · Cited by 181
Current biology of VEGF-B and VEGF-C
Olofsson, B., Jeltsch, M., Eriksson, U., & Alitalo, K. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)00024-5 · Cited by 179
Role of lymphangiogenic factors in tumor metastasis
He, Y., Karpanen, T., & Alitalo, K. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2003.07.003 · Cited by 179
Wiring the Vascular Network with Neural Cues: A CNS Perspective
Wälchli, T., Wacker, A., Frei, K., Regli, L., Schwab, M. E., Hoerstrup, S. P., Gerhardt, H., & Engelhardt, B. (2015) · Neuron · doi:10.1016/j.neuron.2015.06.038 · Cited by 178
McCarty, M. F., Somcio, R. J., Stoeltzing, O., Wey, J., Fan, F., Liu, W., Bucana, C., & Ellis, L. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31334 · Cited by 175
Kuczynski, E. A., Yin, M., Bar-Zion, A., Lee, C. R., Butz, H., Man, S., Daley, F., Vermeulen, P. B., Yousef, G. M., Foster, F. S., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw030 · Cited by 174
Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells
Shojaei, F., & Ferrara, N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0925 · Cited by 171
Sun, B., Zhang, D., Zhang, S., Zhang, W., Guo, H., & Zhao, X. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.08.016 · Cited by 170
Scholz, A., Harter, P. N., Cremer, S., Yalcin, B. H., Gurnik, S., Yamaji, M., Di Tacchio, M., Sommer, K., Baumgarten, P., Bähr, O., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505505 · Cited by 169
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
Rosen, L. S., Jacobs, I. A., & Burkes, R. L. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0518-1 · Cited by 168
Cascone, T., Herynk, M. H., Xu, L., Du, Z., Kadara, H., Nilsson, M. B., Oborn, C. J., Park, Y.-Y., Erez, B., Jacoby, J. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42405 · Cited by 164
Carbonell, W. S., DeLay, M., Jahangiri, A., Park, C. C., & Aghi, M. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0011 · Cited by 163
Xu, Y., Li, Q., Li, X.-Y., Yang, Q.-Y., Xu, W.-W., & Liu, G.-L. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-16 · Cited by 160
PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
Bais, C., Wu, X., Yao, J. J., Yang, S., Crawford, Y., McCutcheon, K. M., Tan, C., Kolumam, G. A., Vernes, J.-M., Eastham‐Anderson, J., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.033 · Cited by 159
Passardi, A., Scarpi, E., Cavanna, L., Dall’Agata, M., Tassinari, D., Leo, S., Bernardini, I., Gelsomino, F., Tamberi, S., Brandes, A. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8901 · Cited by 159
Cited by
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Ganesh, K., & Massagué, J. (2021) · Nature Medicine · doi:10.1038/s41591-020-01195-4 · Cited by 1,051
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Wang, B., Zhao, Q., Zhang, Y., Liu, Z., Zheng, Z., Liu, S., Meng, L., Xin, Y., & Jiang, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01820-7 · Cited by 315
Metadata
- Authors
- Haibe, Y., Kreidieh, M., El Hajj, H., Khalifeh, I., Mukherji, D., Temraz, S., & Shamseddine, A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-02-27
- Volume
- 10
- Pages
- 221-221
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3007442940
- Cited by
- 396
- References
- 302
- FWCI
- 15.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.